Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 4, Number 5, October 2012, pages 309-313


Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients

Tables

Table 1. Univariate Correlation Between Changes of Parameters During 12 Weeks’ Sitagliptin Treatment
 
ΔCrΔUA
Correlations among blood pressure, creatinine, and uric acid levels; correlation between changes in ALP and HbA1c.
ΔSBPr-0.236-0.134
P< 0.01< 0.05
ΔDBPr-0.161-0.079
P< 0.01NS
ΔCrr0.342
P< 0.01
ΔHbA1c
ΔALPr0.383
P< 0.01

 

Table 2. HbA1c, Blood Pressure, Lipid Profile, and Laboratory Data Over Time During Sitagliptin Treatment
 
0 weeks4 weeks12 weeks
ANOVA: vs. baseline ** P < 0.01 * P < 0.05vs. 4 weeks †† P < 0.01.
HbA1c (%)8.02 ± 1.127.71 ± 0.98 **7.38 ± 0.89 **,††
SBP (mmHg)128.8 ± 14.3127.6 ± 13.7*127.4 ± 13.4**
DBP (mmHg)74.7 ± 9.874.0 ± 9.674.0 ± 9.3*
TCHOL198.2 ± 34.3192.6 ± 34.3**191.7 ± 32.5**
HDL (mg/dL)57.1 ± 15.256.4 ± 14.956.2 ± 14.8
ppTGs (mg/dL)157.4 ± 99.4144.9 ± 87.2*146.3 ± 86.8*
fTGs (mg/dL)132.4 ± 141.2125.0 ± 107.4136.9 ± 125.2
Cr (mg/dL)0.75 ± 0.220.77 ± 0.23**0.78 ± 0.24**
UA (mg/dL)5.07 ± 1.215.28 ± 1.32**5.40 ± 1.45**
ALP (IU/L)255.3 ± 93.0240.3 ± 86.1**231.8 ± 78.2**
GOT (IU/L)25.3 ± 15.925.5 ± 18.625.3 ± 18.0
GPT (IU/L)27.7 ± 21.226.3 ± 21.726.9 ± 22.8
γGTP (IU/L)45.7 ± 50.444.1 ± 55.344.8 ± 54.9
LDH (IU/L)244.6 ± 63.2249 ± 60.2246 ± 52.6